已收盤 09-05 16:00:00 美东时间
+0.050
+2.12%
Celularity Inc. filed its Q2 and Q1 2025 Form 10-Q quarterly reports on August 29, 2025, aligning with its updated Nasdaq compliance plan. The company regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing. CEO Robert J. Hariri highlighted the retirement of $32 million in senior secured debt and $9.6 million in interest, as well as internal restructuring and agreements with Celeniv Pte. Ltd. Celularity faces challenges, incl...
09-03 12:00
今日重点评级关注:Craig-Hallum:维持Applied Digital"买入"评级,目标价从12美元升至23美元;HC Wainwright & Co.:维持Bitdeer Technologies"买入"评级,目标价从18美元升至19美元
08-19 09:56
Celularity ( ($CELU) ) has shared an announcement. On August 13, 2025, Celulari...
08-19 05:01
Celularity Inc. announced the completion of a major balance sheet restructuring, retiring all $32.0 million of senior secured debt plus $9.6 million in associated unpaid interest. The company entered into an Asset Purchase Agreement with Celeniv Pte. Ltd., selling its intellectual property assets while retaining exclusive use through a License Agreement. Celularity also completed an internal restructuring, establishing wholly owned operating subs...
08-18 12:00
Celularity ( ($CELU) ) has shared an update. On July 14, 2025, Celularity Inc. ...
07-31 05:21
Celularity ( ($CELU) ) just unveiled an announcement. On June 23, 2025, Celular...
07-23 05:04
Shares of Data Storage Corporation (NASDAQ:DTST) rose sharply in pre-market tra...
07-16 18:04
Celularity Inc. has entered into a strategic partnership with Fountain Life to supply stem cell therapy products under Florida's new law, effective July 1, 2025, which allows licensed physicians to administer stem cell therapies for orthopedic, wound care, and pain management conditions without FDA IND approval. Fountain Life operates four longevity centers in the U.S., including two in Florida, and plans to deploy Celularity’s placenta-derived s...
07-09 12:30
A new Florida law effective July 1 allows physicians to offer investigational stem cell therapies for orthopedics, wound care, and pain management under strict patient safety and ethical standards. Celularity Inc., a leader in ethically sourced stem cell therapies, commends the legislation and is prepared to supply the necessary stem cells, manufactured in FDA-registered facilities. The law requires informed consent and limits stem cell sources t...
07-01 12:30
Celularity (NASDAQ:CELU) terminated the employment of its chief financial officer, David Beers, effective immediately. Beers was terminated “without cause” under the terms of his employment agreement....
06-11 04:21